• 1
    Boyle P, Severi G, Giles GG. The epidemiology of prostate cancer. Urol Clin North Am. 2003; 30: 209-217.
  • 2
    Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004; 22: 2141-2149.
  • 3
    Korfage IJ, Essink-Bot ML, Borsboom GJ, et al. Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer. 2005; 116: 291-296.
  • 4
    Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008; 358: 1250-1261.
  • 5
    Choo R, Klotz L, Danjoux C, et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol. 2002; 167: 1664-1669.
  • 6
    van den Bergh RC, Roemeling S, Roobol MJ, Roobol W, Schroder FH, Bangma CH. Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol. 2007; 52: 1560-1563.
  • 7
    Parker C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol. 2004; 5: 101-106.
  • 8
    Wallace M. Uncertainty and quality of life of older men who undergo watchful waiting for prostate cancer. Oncol Nurs Forum. 2003; 30: 303-309.
  • 9
    O'Connor AM. Validation of a decisional conflict scale. Med Decis Making. 1995; 15: 25-30.
  • 10
    University of Ottawa. Decisional Conflict Scale-User Manual. Ottawa, Ontario, Canada: Ottawa Health Decision Centre at the Ottawa Health Research Institute, University of Ottawa; 2006. Available at: Accessed October 6, 2008.
  • 11
    Roberts RE, Vernon SW. The Center for Epidemiologic Studies Depression Scale: its use in a community sample. Am J Psychiatry. 1983; 140: 41-46.
  • 12
    Myers JK, Weissman MM. Use of a self-report symptom scale to detect depression in a community sample. Am J Psychiatry. 1980; 137: 1081-1084.
  • 13
    Marteau TM, Bekker H. The development of a 6-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). Br J Clin Psychol. 1992; 31( pt 3): 301-306.
  • 14
    Millar K, Jelicic M, Bonke B, Asbury AJ. Assessment of preoperative anxiety: comparison of measures in patients awaiting surgery for breast cancer. Br J Anaesth. 1995; 74: 180-183.
  • 15
    Roth AJ, Rosenfeld B, Kornblith AB, et al. The Memorial Anxiety Scale for Prostate Cancer: validation of a new scale to measure anxiety in men with prostate cancer. Cancer. 2003; 97: 2910-2918.
  • 16
    Roth A, Nelson CJ, Rosenfeld B, et al. Assessing anxiety in men with prostate cancer: further data on the reliability and validity of the Memorial Anxiety Scale for Prostate Cancer (MAX-PC). Psychosomatics. 2006; 47: 340-347.
  • 17
    Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996; 34: 220-233.
  • 18
    Eysenck HJ, Eysenck SBG. Manual of the Eysenck Personality Scales (EPS Adult). London, United Kingdom: Hodder & Stoughton; 1991.
  • 19
    Koedoot N, Molenaar S, Oosterveld P, et al. The decisional conflict scale: further validation in 2 samples of Dutch oncology patients. Patient Educ Couns. 2001; 45: 187-193.
  • 20
    Beekman AT, van Limbeek J, Deeg DJ, Wouters L, van Tilburg W. [A screening tool for depression in the elderly in the general population: the usefulness of Center for Epidemiological Studies Depression Scale (CES-D)]. Tijdschr Gerontol Geriatr. 1994; 25: 95-103.
  • 21
    van der Bij AK, de Weerd S, Cikot RJ, Steegers EA, Braspenning JC. Validation of the Dutch short form of the state scale of the Spielberger State-Trait Anxiety Inventory: considerations for usage in screening outcomes. Community Genet. 2003; 6: 84-87.
  • 22
    Razavi D, Gandek B. Testing Dutch and French translations of the SF-36 Health Survey among Belgian angina patients. J Clin Epidemiol. 1998; 51: 975-981.
  • 23
    Sanderman R, Arindell WA, Ranchor AV, Eysenck HJ, Eysenck SBG. Het meten van persoonlijkheidskenmerken met de Eysenck Personality Questionnaire (EPQ): Een handleiding. Noordelijk Centrum voor Gezondheidsvraagstukken. [Measuring personality traits using the Eysenck Personality Questionnaire (EPQ): a manual. Northern Centre for Health Issues.] Groningen, the Netherlands: Rijsuniversiteit Groningen; 1995.
  • 24
    Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol. 1993; 46: 1417-1432.
  • 25
    Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003; 41: 582-592.
  • 26
    Orom H, Penner LA, West BT, Downs TM, Rayford W, Underwood W. Personality predicts prostate cancer treatment decision-making difficulty and satisfaction. Psychooncology. 2009: 18: 290-299.
  • 27
    Pickles T, Ruether JD, Weir L, Carlson L, Jakulj F. Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance. BJU Int. 2007; 100: 544-551.
  • 28
    Steginga SK, Occhipinti S, Gardiner RA, Yaxley J, Heathcote P. Prospective study of men's psychological and decision-related adjustment after treatment for localized prostate cancer. Urology. 2004; 63: 751-756.
  • 29
    Korfage IJ, Essink-Bot ML, Janssens AC, Schroder FH, de Koning HJ. Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up. Br J Cancer. 2006; 94: 1093-1098.
  • 30
    Litwin MS, Lubeck DP, Spitalny GM, Henning JM, Carroll PR. Mental health in men treated for early stage prostate carcinoma: a post-treatment, longitudinal quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer. 2002; 95: 54-60.
  • 31
    Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med. 2002; 347: 790-796.
  • 32
    Burnet KL, Parker C, Dearnaley D, Brewin CR, Watson M. Does active surveillance for men with localized prostate cancer carry psychological morbidity? BJU Int. 2007; 100: 540-543.
  • 33
    Blank TO, Bellizzi KM. After prostate cancer: predictors of well being among long-term prostate cancer survivors. Cancer. 2006; 106: 2128-2135.
  • 34
    Bisson JI, Chubb HL, Bennett S, Mason M, Jones D, Kynaston H. The prevalence and predictors of psychological distress in patients with early localized prostate cancer. BJU Int. 2002; 90: 56-61.
  • 35
    Donovan J, Hamdy F, Neal D, et al. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess. 2003; 7: 1-88.
  • 36
    Latini DM, Hart SL, Knight SJ, et al. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol. 2007; 178: 826-831; discussion 831-832.
  • 37
    Daubenmier JJ, Weidner G, Marlin R, et al. Lifestyle and health-related quality of life of men with prostate cancer managed with active surveillance. Urology. 2006; 67: 125-130.
  • 38
    Bailey DE, Mishel MH, Belyea M, Stewart JL, Mohler J. Uncertainty intervention for watchful waiting in prostate cancer. Cancer Nurs. 2004; 27: 339-346.
  • 39
    Kronenwetter C, Weidner G, Pettengill E, et al. A qualitative analysis of interviews of men with early stage prostate cancer: the Prostate Cancer Lifestyle Trial. Cancer Nurs. 2005; 28: 99-107.